Roeland Hanemaaijer

List of Publications by Year
in descending order

64 papers	4,353 citations	81900 39 h-index	123424 61 g-index
64 all docs	64 docs citations	64 times ranked	6182 citing authors

#	Article	IF	Citations
1	Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-Î² Signaling Pathways in Human Hepatic Stellate Cells. Biomedicines, 2021, 9, 1954.	3.2	23
2	Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 83-98.e10.	4.5	44
3	Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlrâ€/â€.Leiden Mice. Hepatology Communications, 2018, 2, 1513-1532.	4.3	49
4	Key Inflammatory Processes in Human NASH Are Reflected in Ldlrâˆ'/âˆ'.Leiden Mice: A Translational Gene Profiling Study. Frontiers in Physiology, 2018, 9, 132.	2.8	35
5	Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction. Cardiovascular Research, 2016, 109, 67-78.	3.8	103
6	Extracellular matrix proteins: A positive feedback loop in lung fibrosis?. Matrix Biology, 2014, 34, 170-178.	3.6	76
7	Role of caveolin-1 in fibrotic diseases. Matrix Biology, 2013, 32, 307-315.	3.6	89
8	Identification of Free Nitric Oxide Radicals in Rat Bone Marrow: Implications for Progenitor Cell Mobilization in Hypertension. PLoS ONE, 2013, 8, e57761.	2.5	12
9	Stimulation of Fibrotic Processes by the Infrapatellar Fat Pad in Cultured Synoviocytes From Patients With Osteoarthritis: A Possible Role for Prostaglandin F_{2Î±}. Arthritis and Rheumatism, 2013, 65, 2070-2080.	6.7	66
10	Impaired Collagen Biosynthesis and Crossâ€linking in Aorta of Patients With Bicuspid Aortic Valve. Journal of the American Heart Association, 2013, 2, e000034.	3.7	53
11	A Clinical Evaluation of Statin Pleiotropy: Statins Selectively and Dose-Dependently Reduce Vascular Inflammation. PLoS ONE, 2013, 8, e53882.	2.5	87
12	Cyclic mechanical stretch reduces myofibroblast differentiation of primary lung fibroblasts. Biochemical and Biophysical Research Communications, 2011, 404, 23-27.	2.1	69
13	Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy?. Clinical Biochemistry, 2010, 43, 635-639.	1.9	45
14	The pathophysiology of abdominal aortic aneurysm growth: Corresponding and discordant inflammatory and proteolytic processes in abdominal aortic and popliteal artery aneurysms. Journal of Vascular Surgery, 2010, 51, 1479-1487.	1.1	103
15	Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta OncolÃ³gica, 2010, 49, 1283-1287.	1.8	37
16	Straining Modeâ€"Dependent Collagen Remodeling in Engineered Cardiovascular Tissue. Tissue Engineering - Part A, 2009, 15, 841-849.	3.1	21
17	Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovascular Pathology, 2009, 18, 37-43.	1.6	93
18	Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. Journal of Vascular Surgery, 2009, 49, 741-749.	1.1	96

#	Article	IF	Citations
19	Erosive arthritis in a patient with pycnodysostosis: An experiment of nature. Arthritis and Rheumatism, 2008, 58, 3394-3401.	6.7	13
20	Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. American Journal of Physiology - Renal Physiology, 2007, 293, F1927-F1934.	2.7	32
21	Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. European Journal of Cancer, 2007, 43, 1869-1876.	2.8	128
22	Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biology, 2007, 27, 267-71.	3.6	13
23	Collagen Degradation in the Abdominal Aneurysm. American Journal of Pathology, 2007, 170, 809-817.	3.8	166
24	Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Translational Research, 2007, 149, 137-144.	5.0	57
25	Effect of the anti-tumor necrosis factor-Î± antibody infliximab on the ex vivo mucosal matrix metalloproteinaseâ€“proteolytic phenotype in inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 200-210.	1.9	59
26	Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. Journal of Neuroimmunology, 2007, 187, 179-186.	2.3	51
27	Human osteoblasts produce cathepsin K. Bone, 2006, 38, 769-777.	2.9	64
28	Increased collagen degradation around loosened total hip replacement implants. Arthritis and Rheumatism, 2006, 54, 2928-2933.	6.7	29
29	EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. International Journal of Cancer, 2006, 118, 2991-2998.	5.1	49
30	Membrane-type matrix metalloproteinases and vascularization in human endometrium during the menstrual cycle. Molecular Human Reproduction, 2006, 12, 11-18.	2.8	25
31	Detection of a Soluble Form of BACE-1 in Human Cerebrospinal Fluid by a Sensitive Activity Assay. Clinical Chemistry, 2006, 52, 1168-1174.	3.2	66
32	Levels of matrix metalloproteinase-2, â^'9 and â^'8 in the skin, serum and saliva of smokers and non-smokers. Archives of Dermatological Research, 2005, 297, 242-248.	1.9	38
33	Involvement of Membrane-Type Matrix Metalloproteinases (MT-MMPs) in Capillary Tube Formation by Human Endometrial Microvascular Endothelial Cells: Role of MT3-MMP. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5828-5836.	3.6	67
34	The Fibrinolytic System and Matrix Metalloproteinases in Angiogenesis and Tumor Progression. Seminars in Thrombosis and Hemostasis, 2004, 30, 71-82.	2.7	19
35	Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis. Nephrology Dialysis Transplantation, 2004, 19, 1412-1419.	0.7	48
36	Cathepsin K Is the Principal Protease in Giant Cell Tumor of Bone. American Journal of Pathology, 2004, 165, 593-600.	3.8	113

#	Article	IF	Citations
37	Gelatinase B is associated with peri-implant bone loss. Clinical Oral Implants Research, 2003, 14, 709-713.	4.5	32
38	Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. Journal of Surgical Research, 2003, 111, 45-52.	1.6	28
39	Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis. Journal of Biological Chemistry, 2003, 278, 40967-40972.	3.4	333
40	Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood, 2003, 101, 1810-1817.	1.4	143
41	Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. Thrombosis and Haemostasis, 2003, 89, 718-725.	3.4	48
42	Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anti-Cancer Drugs, 2002, 13, 245-254.	1.4	91
43	Inhibition of matrix metalloproteinases (MMPs) by tetracyclines. , 2001, , 267-281.		10
44	Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood, 2001, 97, 3123-3131.	1.4	100
45	Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis and Rheumatism, 2001, 44, 1908-1916.	6.7	58
46	Increased gelatinase-A and gelatinase-B activities in malignantvs. benign breast tumors. International Journal of Cancer, 2000, 86, 204-207.	5.1	99
47	Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma. Blood, 2000, 96, 4006-4007.	1.4	22
48	Metalloproteinase Inhibition Reduces Constrictive Arterial Remodeling After Balloon Angioplasty. Circulation, 2000, 101, 2962-2967.	1.6	113
49	Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma. Blood, 2000, 96, 4006-4007.	1.4	0
50	MMP Inhibition and Downregulation by Bisphosphonates. Annals of the New York Academy of Sciences, 1999, 878, 453-465.	3.8	178
51	Determination of Gelatinase-A (MMP-2) Activity Using a Novel Immunocapture Assay. Annals of the New York Academy of Sciences, 1999, 878, 487-490.	3.8	21
52	Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biology, 1999, 18, 401-412.	3.6	74
53	Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of SjÃ¶gren's syndrome. Matrix Biology, 1998, 17, 335-347.	3.6	89
54	A novel and simple immunocapture assay for determination of gelatinase-b (MMP-9) activities in biological fluids: Saliva from patients with SjÃ¶gren's Syndrome contain increased latent and active gelatinase-b levels. Matrix Biology, 1998, 17, 657-665.	3.6	111

#	Article	IF	Citations
55	Proteases and Angiogenesis. Regulation of Plasminogen Activators and Matrix Metalloproteases by Endothelial Cells. , 1998, , 241-261.		1
56	Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochemical Journal, 1997, 323, 603-609.	3.7	81
57	Matrix Metalloproteinase-8 Is Expressed in Rheumatoid Synovial Fibroblasts and Endothelial Cells. Journal of Biological Chemistry, 1997, 272, 31504-31509.	3.4	428
58	Structure/function relationships in the pyruvate dehydrogenase complex form Azotobacter vinelandii. Role of the linker region between the binding and catalytic domain of the dihydrolipoyl transacetylase component. FEBS Journal, 1993, 211, 591-599.	0.2	6
59	The quaternary structure of the dihydrolipoyl transacetylase component of the pyruvate dehydrogenase complex from Azotobacter vinelandii. A reconsideration. FEBS Journal, 1989, 179, 287-292.	0.2	18
60	The gene encoding dihydrolipoyl transacetylase from Azotobacter vinelandii. Expression in Escherichia coli and activation and isolation of the protein. FEBS Journal, 1989, 181, 47-53.	0.2	17
61	The dihydrolipoyltransacetylase component of the pyruvate dehydrogenase complex from Azotobacter vinelandii. Molecular cloning and sequence analysis. FEBS Journal, 1988, 174, 593-599.	0.2	69
62	Mobile sequences in the pyruvate dehydrogenase complex, the E2component, the catalytic domain and the 2-oxoglutarate dehydrogenase complex ofAzotobacter vinelandii, as detected by 600 MHz1H-NMR spectroscopy. FEBS Letters, 1988, 240, 205-210.	2.8	6
63	Time-resolved fluorescence studies on the dihydrolipoyl transacetylase (E2) component of the pyruvate dehydrogenase complex fromAzotobacter vinelandii. FEBS Letters, 1988, 238, 285-288.	2.8	6
64	The domain structure of the dihydrolipoyl transacetylase component of the pyruvate dehydrogenase complex from Azotobacter vinelandii. FEBS Journal, 1987, 169, 245-252.	0.2	33